Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee Conflict Of Interest Policy Simplified In Draft Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA presents a consolidated, step-by-step policy to determine eligibility of possible advisory committee participants.

You may also be interested in...



Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting

Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia

Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting

Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia

FDA Must Maintain Conflict of Interest Waivers, Gottlieb Argues

The inability to issue conflict of interest waivers would diminish advisory panels’ importance to the agency, the Deputy Commissioner for Medical & Scientific Affairs said at an event on government panels.

Related Content

Topics

UsernamePublicRestriction

Register

PS065786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel